Nanococktail Based on Supramolecular Glyco-Assembly for Eradicating Tumors In Vivo

Weiwei Feng,Shangqian Zhang,Yichen Wan,Zelong Chen,Yun Qu,Jiahui Li,Tony D. James,Zhichao Pei,Yuxin Pei
DOI: https://doi.org/10.1021/acsami.2c03463
IF: 9.5
2022-04-28
ACS Applied Materials & Interfaces
Abstract:The development of robust phototherapeutic strategies for eradicating tumors remains a significant challenge in the transfer of cancer phototherapy to clinical practice. Here, a phototherapeutic nanococktail atovaquone/17-dimethylaminoethylamino-17-demethoxygeldanamycin/glyco-BODIPY (ADB) was developed to enhance photodynamic therapy (PDT) and photothermal therapy (PTT) via alleviation of hypoxia and thermal resistance that was constructed using supramolecular self-assembly of glyco-BODIPY (BODIPY-SS-LAC, BSL-1), hypoxia reliever atovaquone (ATO), and heat shock protein inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG). Benefiting from a glyco-targeting and glutathione (GSH) responsive units BSL-1, ADB can be rapidly taken up by hepatoma cells, furthermore the loaded ATO and 17-DMAG can be released in original form into the cytoplasm. Using <i>in vitro</i> and <i>in vivo</i> results, it was confirmed that ADB enhanced the synergetic PDT and PTT upon irradiation using 685 nm near-infrared light (NIR) under a hypoxic tumor microenvironment where ATO can reduce O<sub>2</sub> consumption and 17-DMAG can down-regulate HSP90. Moreover, ADB exhibited good biosafety, and tumor eradication <i>in vivo</i>. Hence, this as-developed phototherapeutic nanococktail overcomes the substantial obstacles encountered by phototherapy in tumor treatment and offers a promising approach for the eradication of tumors.
materials science, multidisciplinary,nanoscience & nanotechnology
What problem does this paper attempt to address?